Has the time come to end use of the blue inhaler?
Author:
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine
Reference8 articles.
1. Treatment of mild-to-moderate asthma in childhood and adolescence in 2021;Abrams;Lancet Respir Med,2021
2. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis;Rogliani;Eur Respir J,2020
3. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma;Bisgaard;Chest,2006
4. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma;O'Byrne;Am J Respir Crit Care Med,2005
5. End of the New Zealand asthma mortality epidemic;Pearce;Lancet,1995
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Update in paediatric asthma 2024;Pediatric Respirology and Critical Care Medicine;2024-01
2. Advances in the pathogenesis and personalised treatment of paediatric asthma;BMJ Medicine;2023-06
3. Global Initiative for Asthma 2021: Asthma in Preschool Children and Short-Acting β2-Agonist–Only Treatment;American Journal of Respiratory and Critical Care Medicine;2022-04-15
4. The Children's Anti-inflammatory Reliever (CARE) study: a protocol for a randomised controlled trial of budesonide-formoterol as sole reliever therapy in children with mild asthma;ERJ Open Research;2021-07-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3